Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PBI-4050 in Idiopathic Pulmonary Fibrosis
NCT02538536Phase 2Completed
- Sponsor
- Liminal BioSciences Inc.
- Start
- Jul 2015
- Primary completion
- Jan 2017
- Countries
- 1
01
Overview
A Phase 2 trial of fezagepras in idiopathic pulmonary fibrosis (IPF), sponsored by Liminal BioSciences Inc.. Started Jul 2015; status: completed.
02
Drugs
fezagepras
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT02538536.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02538536.